MGO One Seven LLC Acquires 33,377 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

MGO One Seven LLC grew its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 216.2% in the 4th quarter, Holdings Channel reports. The fund owned 48,813 shares of the company’s stock after purchasing an additional 33,377 shares during the quarter. MGO One Seven LLC’s holdings in Teva Pharmaceutical Industries were worth $1,076,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Price T Rowe Associates Inc. MD raised its stake in Teva Pharmaceutical Industries by 148.3% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,049,388 shares of the company’s stock valued at $45,170,000 after purchasing an additional 1,223,957 shares during the last quarter. Dark Forest Capital Management LP bought a new stake in shares of Teva Pharmaceutical Industries in the fourth quarter valued at about $441,000. BlackBarn Capital Partners LP grew its position in Teva Pharmaceutical Industries by 107.1% during the fourth quarter. BlackBarn Capital Partners LP now owns 1,050,000 shares of the company’s stock worth $23,142,000 after buying an additional 543,029 shares in the last quarter. Diadema Partners LP bought a new position in Teva Pharmaceutical Industries during the fourth quarter valued at about $6,677,000. Finally, Hsbc Holdings PLC raised its holdings in Teva Pharmaceutical Industries by 5.7% in the 4th quarter. Hsbc Holdings PLC now owns 561,289 shares of the company’s stock valued at $12,374,000 after acquiring an additional 30,155 shares in the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Stock Performance

NYSE TEVA opened at $14.88 on Friday. Teva Pharmaceutical Industries Limited has a 1-year low of $12.47 and a 1-year high of $22.80. The company has a 50 day moving average of $15.23 and a 200-day moving average of $17.56. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97. The firm has a market cap of $16.87 billion, a price-to-earnings ratio of -10.26, a PEG ratio of 1.44 and a beta of 0.72.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, beating analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. On average, equities analysts forecast that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently weighed in on TEVA shares. UBS Group decreased their price objective on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a report on Thursday, January 30th. Bank of America dropped their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating for the company in a research note on Thursday, March 6th. Barclays decreased their target price on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a research report on Thursday, January 30th. Piper Sandler increased their price target on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a research report on Friday, January 17th. Finally, StockNews.com upgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research note on Wednesday. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $23.43.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.